Unapproved peptides are reaching patients before critical safety questions are answered.
In @medpagetoday oncologist Dr. Gilberto de Lima Lopes Junior warns of unknown long-term risks, including potential concerns involving tumor growth pathways.
https://t.co/ju4yqQs1pv
A recent shift in federal enforcement policy has prompted telehealth companies and other providers to begin offering unapproved peptide treatments, despite significant gaps in evidence about their safety and effectiveness. Read ASEM's full statement: https://t.co/uXOJ7Uc62t
A woman suffered acute liver failure after injecting a black-market product sold as retatrutide.
As the @nypost reports, sales of unapproved peptides carry serious risks. Regulators must crack down before more patients are harmed.
Read more: https://t.co/71HDr1EqEo
1 in 5 Americans has been tricked into buying counterfeit medications online. ASEM Chief Policy Officer Fred H. Mills Jr. shares a warning about using medicines purchased from unverified sellers and offers advice on how to spot counterfeit drugs: https://t.co/dZfE4t7PME
“Lowering the bar is no substitute for meeting it.”
Former @HHSGov Secretary Tom Price warns that loosening restrictions on unapproved peptides could undermine the rigorous safety standards patients depend on.
Read his thoughts in @dcexaminer: https://t.co/OYh10SZFie
In a new #DocsWhoLift episode, @DrKarlNadolsky & @DrNadolsky discuss with Dr. Leigh Baxt why unapproved peptides like BPC-157 still need rigorous safety testing—and why social media hype isn't enough. Listen: https://t.co/xyqJzqVpYm
A new analysis by @ACSHorg breaks down the science behind peptides and the risks of allowing unapproved drugs to reach consumers without adaquate oversight. Patients deserve treatments backed by clinical evidence, not marketing claims.
Read more: https://t.co/f2R00WTNTy
Unapproved peptides are being marketed online with promises of better health, despite serious gaps in scientific evidence. They have not undergone FDA review for safety and effectiveness, leaving patients exposed to risks. Learn more: https://t.co/XWIfRcZG9W
New coverage from @stopafib highlights how misleading ads for unapproved drugs like retatrutide put older Americans at risk and calls on @SenateAging to help protect seniors from illegally marketed medicines.
Read more: https://t.co/GEFO21AIC6
ASEM is urging @HHSGov to withdraw its policy allowing the compounding of six unapproved peptides despite serious safety concerns.
The public comment period closes Nov. 13. Join our call to put patient safety first by signing on to our letter: https://t.co/XWIfRd0dZu
Peter Pitts, President of The Center for Medicine in the Public Interest for Medicine in the Public Interest and former FDA Associate Commissioner, sends a call to action to his former agency. Federal agencies must take action to protect patients before it's too late.
Online clinics. Gyms. Even a bodega. @CBSNews found it shockingly easy to buy unapproved "reta." None of the products were verified as the clinical-trial drug, and one vial even contained bacteria. @FDA and law enforcement must crack down on illegal sales. https://t.co/7iMGHC4oeY
FDA scientists raised safety concerns about seven experimental peptides. An advisory committee voted to allow six to be compounded.
Now, @SafeMedicines is urging FDA to reject that recommendation.
Patient safety must come before expanded access. https://t.co/jxzsAmL7ey
We stand with the @ncl_tweets in urging FDA not to weaken safety standards for unapproved peptides.
Patients deserve medicines backed by science, not regulatory shortcuts that put their health at risk.
Read NCL's statement: https://t.co/eX8QhE8wB7
The tirzepatide shortage ended nearly two years ago, yet Apothecary Pharma is now recalling compounded versions over sterility concerns. Why are companies still mass-producing copies of FDA-approved drugs? FDA must enforce its rules and protect patients. https://t.co/VDf0wLebae
@HHSGov 's new peptide policy has businesses seeing dollar signs.
Companies are already rushing to market unapproved products, while serious questions about their safety remain unanswered.
More here: https://t.co/GuzRm6FyRW
"A brief online questionnaire shouldn't be a shortcut to obtaining unapproved weight-loss drugs.
ASEM's Fred Mills responds to @TIME's reporting on compounded GLP-1s, calling for stronger FDA enforcement and accountability for bad actors.
https://t.co/4pSdahR5qN"
Compounding is meant to meet individual patient needs, not provide a workaround for FDA approval. Former FDA official Peter Pitts examines how some compounders are exploiting that distinction and why FDA must follow through when violations persist. Read: https://t.co/aF7lYgrdMX
A new pathway for experimental peptides doesn't erase the safety risks.
Following @HHSGov's decision to expand access to six unapproved peptides, ASEM is raising concerns about the lack of scientific evidence and oversight.
Full statement: https://t.co/nXJpIauOGe
FDA inspectors found alarming conditions at two Chinese facilities supplying ingredients for compounded GLP-1 drugs. Placing these manufacturers on import alert is a step in the right direction. FDA must keep up enforcement to protect patients. @Bloomberg https://t.co/Kf4MwANyAi